Background: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV
infection and is a recommended intervention for HIV-negative persons with substantial HIV …

Summary Background In the UK, HIV incidence among men who have sex with men (MSM)
has remained high for several years, despite widespread use of antiretroviral therapy and …

Introduction: Questions remain whether HIV pre-exposure prophylaxis (PrEP) can be
translated into a successful public health intervention, leading to a decrease in population …

Background Pre-exposure prophylaxis (PrEP) is a promising new HIV prevention method,
especially for women. An urgent demand for implementation of PrEP is expected at the …

Introduction It is increasingly clear that the HIV response will not be sustainable if the
number of infections is not significantly reduced. Discussion For two decades, research has …

The US Food and Drug Administration (FDA) has approved the use of Truvada®(a fıxed-
dose combination of emtricitabine and tenofovir disoproxil fumarate) as pre-exposure …

Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and
bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here …

Introduction Despite a number of HIV prevention strategies, the number of new HIV
infections remains high. In Australia, over three-quarters of new HIV diagnoses are in gay …

Background Reproductive-age women need effective interventions to prevent the
acquisition of human immunodeficiency virus type 1 (HIV-1) infection. Methods We …

Abstract Purpose of Review The aim of this study is to summarise the recent evidence from
high-income settings about providers' ability to deliver on the UNAIDS goal of at least three …